RT Journal Article
SR Electronic
T1 Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center study.
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.15.24310384
DO 10.1101/2024.07.15.24310384
A1 Gentile, Ivan
A1 Viceconte, Giulio
A1 Cuccurullo, Federica
A1 Pietroluongo, Daria
A1 D'Agostino, Alessia
A1 Silvitelli, Maria
A1 Mercinelli, Simona
A1 Scotto, Riccardo
A1 Grimaldi, Francesco
A1 Palmieri, Salvatore
A1 Gravetti, Angela
A1 Trastulli, Fabio
A1 Moccia, Marcello
A1 Buonomo, Antonio Riccardo
YR 2024
UL http://medrxiv.org/content/early/2024/07/15/2024.07.15.24310384.abstract
AB Background Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data concerning early combined use of antivirals and monoclonal antibodies in this population are scarce. Research design and methods We performed an observational, prospective study, enrolling immunocompromised outpatient adults with mild-to-moderate COVID-19 treated with a combination of sotrovimab plus one antiviral (remdesivir or nirmatrelvir/ritonavir) within 7 days from symptoms onset. Results We enrolled 52 patients. No patient was hospitalized within 30 days from the disease onset, needed oxygen administration or died within 60 days, or experienced a reinfection or a clinical relapse within 90 days. Clearance rates were 67% and 97% at 14th day after the end of therapy and at the end of follow-up, respectively. Factors associated with longer infection were initiation of therapy after 3 days from symptoms onset, and enrollment more than 180 days from the beginning of the study. However, only the latter factor was independently associated with longer SARS-CoV-2 infection, suggesting a loss of efficacy of this strategy with the evolution of SARS-CoV-2 variants Conclusions Early administration of combination therapy with a direct antiviral and sotrovimab seems to be effective in preventing hospitalization, progression to severe COVID-19 and the development of prolonged/persisting SARS-CoV-2 infection in immunocompromised patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by EU funding within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (project no. PE00000007, INF-ACT)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethical Committee of the University of Naples Federico II (protocol n. 98/22).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors